Edition:
United Kingdom

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

17.68USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$17.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
239,322
52-wk High
$49.21
52-wk Low
$17.05

Select another date:

Thu, Jan 25 2018

BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE

BRIEF-Five Prime Announces Pricing Of Upsized Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Five Prime Announces Proposed Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

BRIEF-Five Prime Therapeutics Submits Investigational New Drug Application For FPA150

* FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150

BRIEF-Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement

* FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

BRIEF-Five Prime posts Q3 loss of $1.54 per share

* Five prime announces third quarter 2017 results and provides business update

BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO

* Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage:

Select another date: